- Q3 2023 Immunic Inc Earnings Call TranscriptNov 14, 2023$0.9902 (+2.16%)Earnings
- Immunic Inc To Discuss Interim Data Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive MS Call TranscriptOct 10, 2023
- Q2 2023 Immunic Inc Earnings Call TranscriptAug 03, 2023$2.13 (-1.39%)Earnings
- Immunic Inc To Host Key Opinion Leaders TranscriptJul 20, 2023
- Q1 2023 Immunic Inc Earnings Call TranscriptMay 11, 2023$1.82 (+1.68%)Earnings
- Immunic Inc To Discuss IMU-856 Clinical Phase 1b Results in Celiac Disease Call TranscriptMay 04, 2023
- Immunic Inc To Discuss Phase 2b CALDOSE-1 Maintenance Phase Data Call TranscriptApr 05, 2023
- Q4 2022 Immunic Inc Earnings Call TranscriptFeb 23, 2023$1.97 (+4.23%)Earnings
- Immunic Inc Celiac Disease R&D Webcast TranscriptFeb 09, 2023
- Immunic Inc Corporate Call TranscriptNov 17, 2022
- Q3 2022 Immunic Inc Earnings Call TranscriptNov 03, 2022$1.58 (-7.60%)Earnings
- Immunic Inc Webinar: IMU-856 Phase 1 SAD/MAD Data in Healthy Human Subjects TranscriptSep 20, 2022
- Q2 2022 Immunic Inc Earnings Call TranscriptAug 04, 2022$4.79 (+23.14%)Earnings
- Immunic Inc Corporate Update TranscriptJun 02, 2022
- Q1 2022 Immunic Inc Earnings Call TranscriptMay 10, 2022$5.5 (+5.36%)Earnings
- Q4 2021 Immunic Inc Earnings Call TranscriptFeb 24, 2022$10.72 (-9.15%)Earnings
- Q3 2021 Immunic Inc Earnings Call TranscriptNov 04, 2021$10.25 (+2.60%)Earnings
- Immunic Inc Discuss Overall MS Development Strategy - Corporate Call TranscriptJul 01, 2021
- Q2 2020 Immunic Inc Earnings Call TranscriptAug 03, 2020Earnings
Immunic Inc To Discuss Phase 2b CALDOSE-1 Maintenance Phase Data Call Transcript
Good morning. I would like to welcome you to Immunic's webcast to present the positive results from our Phase IIb CALDOSE-1 maintenance phase data of vidofludimus calcium in moderate-to-severe ulcerative colitis patients as well as updates on our IMU-935 and IMU-856 programs. My name is Jessica Breu, Head of Investor Relations and Communications at Immunic. I will also be the moderator on today's webcast.
Speaking on the call are our Chief Executive Officer and President, Dr. Daniel Vitt and our Chief Medical Officer, Dr. Andreas Muehler. (Operator Instructions). And this event is being recorded. (Operator Instructions)
Before we begin, I would like to remind you that this presentation may contain forward-looking statements, such statements can be identified by words such as may, will, expect, anticipate, estimate or words with similar meaning, and such statements involve a number of risks and uncertainties that could cause Immunic's actual results to differ materially from those discussed here. Please note that these forward
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)